Literature DB >> 19789373

Analysis of drug interactions involving fruit beverages and organic anion-transporting polypeptides.

David J Greenblatt1.   

Abstract

Recently there has been speculation regarding prescription drug interactions with fruit beverages through inhibition of drug uptake transport by organic anion transporter polypeptides (OATPs). A review of clinical trials indicates that grapefruit juice (GFJ), orange juice (OJ), and apple juice can reduce oral bioavailability of fexofenadine, potentially reducing pharmacodynamic effects of fexofenadine. However, the clinical importance of the interaction is not clearly established. The effect is diminished by temporal separation of fruit juice and fexofenadine administration. GFJ and OJ substantially reduce oral bioavailability of celiprolol, a beta-blocker not available in the United States. Beyond these two examples, other meaningful drug interactions with fruit beverages via OATP inhibition are not established at the present time.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19789373     DOI: 10.1177/0091270009342251

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  14 in total

1.  Interactions of green tea catechins with organic anion-transporting polypeptides.

Authors:  Megan Roth; Barbara N Timmermann; Bruno Hagenbuch
Journal:  Drug Metab Dispos       Date:  2011-01-28       Impact factor: 3.922

2.  Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1.

Authors:  Yoshiyuki Shirasaka; Takanori Mori; Yukiko Murata; Takeo Nakanishi; Ikumi Tamai
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

Review 3.  Influence of dietary substances on intestinal drug metabolism and transport.

Authors:  Christina S Won; Nicholas H Oberlies; Mary F Paine
Journal:  Curr Drug Metab       Date:  2010-11       Impact factor: 3.731

Review 4.  Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response.

Authors:  Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Bruno Flamion; Lars L Gustafsson; Hubert Leufkens; Malcolm Rowland; Christian K Schneider; Brigitte Bloechl-Daum
Journal:  Nat Rev Drug Discov       Date:  2011-07-01       Impact factor: 84.694

5.  Gly45 and Phe555 in Transmembrane Domains 1 and 10 Are Critical for the Activation of Organic Anion Transporting Polypeptide 1B3 by Epigallocatechin Gallate.

Authors:  Mei Yue; Jingjie Yang; Meng Jin; Brianna Steiert; Yiqun Xiang; Hongjian Zhang; Bruno Hagenbuch; Chunshan Gui
Journal:  J Agric Food Chem       Date:  2019-08-06       Impact factor: 5.279

6.  Is pomegranate juice a potential perpetrator of clinical drug-drug interactions? Review of the in vitro, preclinical and clinical evidence.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-05-15       Impact factor: 2.441

Review 7.  The effect of grapefruit juice on drug disposition.

Authors:  Michael J Hanley; Paul Cancalon; Wilbur W Widmer; David J Greenblatt
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01-22       Impact factor: 4.481

8.  Prioritizing pharmacokinetic drug interaction precipitants in natural products: application to OATP inhibitors in grapefruit juice.

Authors:  Emily J Johnson; Christina S Won; Kathleen Köck; Mary F Paine
Journal:  Biopharm Drug Dispos       Date:  2017-02-14       Impact factor: 1.627

9.  A modified grapefruit juice eliminates two compound classes as major mediators of the grapefruit juice-fexofenadine interaction: an in vitro-in vivo "connect".

Authors:  Christina S Won; Tian Lan; Karen M Vandermolen; Paul A Dawson; Nicholas H Oberlies; Wilbur W Widmer; Yolanda V Scarlett; Mary F Paine
Journal:  J Clin Pharmacol       Date:  2013-07-23       Impact factor: 3.126

10.  Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects.

Authors:  Mikko T Holmberg; Aleksi Tornio; Lotta Joutsi-Korhonen; Mikko Neuvonen; Pertti J Neuvonen; Riitta Lassila; Mikko Niemi; Janne T Backman
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.